{"id":"NCT00977106","sponsor":"Hoffmann-La Roche","briefTitle":"TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF","officialTitle":"Comparative Double Blind Placebo Controlled Clinical Study on Tocilizumab Rapid Efficacy on Patients Relief in rheumatoÃ¯d Arthritis With an Inadequate Response to DMARDs or Anti TNF :TORPEDO","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2009-09-15","resultsPosted":"2014-09-22","lastUpdate":"2014-09-22"},"enrollment":103,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"This study will assess the onset and maintenance of effect of tocilizumab on relief in patients with active moderate or severe rheumatoid arthritis who have had an inadequate response to DMARDs or anti-TNF. For the first, double-blind, part of the study patients will be randomized to receive an iv infusion of either 8mg/kg tocilizumab or placebo. After 4 weeks this will be followed by 11 months treatment with tocilizumab 8mg/kg iv infusion every 4 weeks. Methotrexate or DMARD therapy will be continued throughout study treatment. Target sample size is \\>100.","primaryOutcome":{"measure":"Percentage of Participants With Clinically Significant Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 4","timeFrame":"Week 4","effectByArm":[{"arm":"Placebo, Tocilizumab","deltaMin":42,"sd":null},{"arm":"Tocilizumab","deltaMin":49.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.472"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":22,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":53},"commonTop":["Nasopharyngitis","Bronchitis","Gastroenteritis","Diarrhoea","Headache"]}}